Approximately 75% of breast cancers rely on ER signaling to grow and survive.2 Endocrine therapy, which blocks the growth-promoting activity of estrogen, represents the primary intervention for early- and advanced-stage ER-positive breast cancer.3 However, some patients do not respond to endocrine therapy (ie, de novo resistance), and some patients who initially respond to therapy have disease that progresses during therapy (ie, acquired resistance).3

The Journal of Hematology Oncology Pharmacy is pleased to provide readers the Second Annual Oncology Pharmacy Guide to New FDA Approvals. The goal of this Guide is to offer payers, oncology/hematology pharmacists, and other healthcare stakeholders a comprehensive review of novel oncology/hematology drugs that were approved by the US Food and Drug Administration (FDA) in the previous year.
The drugs included in this review were approved by the US Food and Drug Administration (FDA) in 2016.
Chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults, is a cancer of B-cell lymphocytes. More than 20,000 Americans will be diagnosed with CLL in 2017, and 4660 patients with die from the disease.
In the United States, an estimated 12,310 individuals will be diagnosed with soft-tissue sarcoma in 2016, and 4990 will die of the disease.
According to the American Cancer Society, more than 30,280 new cases of multiple myeloma will be diagnosed in 2017, and 12,590 deaths will be attributed to the disease.
Epithelial carcinoma of the ovary is one of the most common gynecologic malignancies. The National Cancer Institute estimates that 22,280 women were diagnosed with ovarian cancer in 2016 and 14,240 women died from the disease.
Chronic lymphocytic leukemia (CLL), a cancer of B-cell lymphocytes, is the most common type of leukemia in adults. According to the American Cancer Society, more than 18,900 Americans will be diagnosed with CLL in 2016.
The Journal of Hematology Oncology Pharmacy has published its first annual Oncology Pharmacy Guide to New FDA Approvals with the goal of providing pharmacists and other healthcare stakeholders with a comprehensive review of pharmaceuticals that were newly approved, or that received important new indications, by the US Food and Drug Administration (FDA) in the previous year. The current 2016 edition represents the first year of publication of this Guide by the Journal of Hematology Oncology Pharmacy.
Page 1 of 3
Results 1 - 10 of 28